Goldline Pharmaceutical SME IPO GMP Today
The Goldline Pharmaceutical SME IPO closed on 14 May 2026. Goldline Pharmaceutical SME IPO GMP is Rs 15.00 today. Listing price estimate is Rs 58.00 (issue price Rs 43.00). Listing gain estimate: 34.88%.
Issue Price
Rs 43.00
GMP Today
Rs 15.00
GMP %
+34.88%
Listing Price
Rs 58.00
Listing Gain / Lot
Rs 90,000.00
Listing Date
19 May 2026
Goldline Pharmaceutical SME IPO GMP Day Wise
GMP for Goldline Pharmaceutical SME started at Rs 0 on 7 May 2026 and stood at Rs 15 on 15 May 2026. The sharpest single-day jump was from Rs 0 on 7 May 2026 to Rs 8 on 8 May 2026. The upward move through the subscription window usually reflects building demand across investor categories rather than a one-day spike.
| Date | Issue Price | GMP | Listing Price | Estimated Profit |
|---|---|---|---|---|
| 15 May 2026Today | Rs 43.00 | Rs 15.00 | Rs 58.00 (+34.88%) | Rs 90,000.00 |
| 14 May 2026 | Rs 43.00 | Rs 15.00 | Rs 58.00 (+34.88%) | Rs 90,000.00 |
| 13 May 2026 | Rs 43.00 | Rs 25.00 | Rs 68.00 (+58.14%) | Rs 1,50,000.00 |
| 12 May 2026 | Rs 43.00 | Rs 18.00 | Rs 61.00 (+41.86%) | Rs 1,08,000.00 |
| 11 May 2026 | Rs 43.00 | Rs 17.00 | Rs 60.00 (+39.53%) | Rs 1,02,000.00 |
| 10 May 2026 | Rs 43.00 | Rs 16.00 | Rs 59.00 (+37.21%) | Rs 96,000.00 |
| 9 May 2026 | Rs 43.00 | Rs 15.00 | Rs 58.00 (+34.88%) | Rs 90,000.00 |
| 8 May 2026 | Rs 43.00 | Rs 8.00 | Rs 51.00 (+18.60%) | Rs 48,000.00 |
| 7 May 2026 | Rs 43.00 | Rs 0.00 | Rs 43.00 (+0.00%) | Rs 0.00 |
Goldline Pharmaceutical SME IPO Listing Price
Based on today's GMP, Goldline Pharmaceutical SME IPO listing price estimate is Rs 58.00 per share (issue price Rs 43.00 + GMP Rs 15.00).
Actual listing price will be known on 19 May 2026 when the stock lists on NSE/BSE.
Goldline Pharmaceutical SME IPO Listing Gain
Lot size: 3000 shares (min. 2 lots for SME)
GMP today: Rs 15.00
Estimated listing gain per lot: Rs 15.00 × 6000 = Rs 90,000.00
A GMP of around 34.9% is a strong positive signal from the grey market. Investors are pricing in a meaningful listing premium over the issue price.
GMP has moved up over the tracked period. Steady increases through the subscription window are usually a stronger signal than a single-day spike.
GMP is unofficial. Listing gain can differ on listing day.
Goldline Pharmaceutical SME IPO Subscription Status
GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. Current overall subscription for Goldline Pharmaceutical SME is 840.81x. Compare this with the GMP trend to see if demand aligns. The GMP move around 8 May 2026 may reflect how the market reacted once the subscription window activity picked up after 12 May 2026.
See live figures on the Goldline Pharmaceutical SME IPO Subscription Status page.
Goldline Pharmaceutical SME IPO Details
| Field | Value |
|---|---|
| Price Band | ₹41.0 - ₹43.0 |
| Issue Size | ₹11.61 Cr |
| Lot Size | 3000 shares |
| IPO Type | BSE SME |
| Open Date | 12 May 2026 |
| Close Date | 14 May 2026 |
| Listing Date | 19 May 2026 |
| Subscription | 840.81x |
Goldline Pharmaceutical SME IPO full details (financials, peers, review).
About Goldline Pharmaceutical SME
Goldline Pharmaceutical Limited, incorporated in 2021, is a pharmaceutical marketing company that operates under an asset-light business model. The company markets a wide range of pharmaceutical formulations under its proprietary brand 'Goldline', across five specialized divisions: Pharma (General), Cardinal (Specialty), Aayushman (Pediatric), InLife (Critical Care), and Wellness (Supportive Care). Instead of in-house manufacturing, Goldline partners with 15 third-party manufacturers and utilizes a network of 7 distributors to supply products to retailers and hospitals across Maharashtra, Tamil Nadu, Rajasthan, and other states.
Goldline Pharmaceutical SME IPO Subscription Status
Live category-wise subscription figures
Goldline Pharmaceutical SME IPO Allotment Status
Check allotment result on allotment date
Goldline Pharmaceutical SME IPO Details
Financials, peers, strengths, and review
IPO GMP Today
GMP for all active IPOs in one table
Goldline Pharmaceutical SME IPO GMP FAQs
What is the current GMP for Goldline Pharmaceutical SME?
The current GMP for Goldline Pharmaceutical SME is Rs 15 as of 11 June 2026, 6:01 AM IST. This is a premium of 34.88% over the issue price of Rs 43.
What is the estimated listing price based on current GMP?
The estimated listing price is Rs 58 per share, calculated as issue price (Rs 43) plus GMP (Rs 15). Actual listing price will be confirmed on 19 May 2026.
Will Goldline Pharmaceutical SME IPO list at the GMP price?
Goldline Pharmaceutical SME IPO may list around Rs 58 based on current GMP of Rs 15, but there is no guarantee it will list exactly at the grey market price. GMP is unofficial. The actual listing price on 19 May 2026 depends on market sentiment, subscription demand, and broader index levels on listing day. When subscription is strong and GMP holds steady after the IPO closes, listing price often comes close to the GMP estimate. Sharp GMP drops after subscription close have led to listings below the grey market price in the past.
What is the estimated profit per lot based on GMP?
At GMP of Rs 15 and lot size of 3000 shares (minimum 2 lots for SME), estimated grey market profit is Rs 90,000 (2 lots x 3000 shares x Rs 15). This is unofficial and not guaranteed.
What is GMP (Grey Market Premium)?
GMP is the premium at which IPO shares trade in the unofficial grey market before listing on NSE or BSE. It reflects informal demand and sentiment, not an exchange-set price.
How is GMP calculated?
Estimated listing price = issue price + GMP. GMP percentage = (GMP / issue price) x 100. Estimated profit per lot = GMP x lot size x minimum lots (2 for SME, 1 for mainboard).
Is GMP reliable for IPO investment decisions?
GMP is a sentiment indicator. Use it with subscription data, financials, valuation, and market conditions. It does not guarantee listing price or listing day gains.
Can GMP change before listing?
Yes. GMP can change between the close date (14 May 2026) and listing date (19 May 2026) based on market mood, news, and broader index movement.
What happens if GMP is negative?
Negative GMP suggests weak informal demand and possible listing below issue price. Actual listing may still differ.
How does GMP affect IPO subscription?
Rising GMP can attract more applications in the final hours of subscription. High GMP with weak fundamentals has still led to poor listings, so read subscription category-wise before applying.
Where can I track Goldline Pharmaceutical SME subscription and allotment?
Check Goldline Pharmaceutical SME IPO subscription status on IPOwiz for live category-wise bids. Allotment status can be checked from the allotment date on the IPOwiz allotment page.
Reviewed by Dinesh Agrawal
15+ years in Indian capital markets and IPO research. GMP verified before publish.